🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

A close friend, Dr Roxana Daneshjou’s story has been on my mind ever since she shared it with me. ❤️‍🩹 Her courage should inspire all of us to be the change and vote!!

Dr. Natalie Vokes at MD Anderson Cancer Center emphasizes PD-L1 is not a biomarker for IO-IO (CTLA4) response. CCND1, CDK4, and cell cycle regulators appear to be associated with worse outcomes with IO-chemo compared to IO monotherapy. #lcam #lcsm #DFHCC #LungCaSymposium24

A very important slide by Jia Luo, MD: Biomarkers are the future, and early detection is the key to transforming outcomes. #PrecisionOncology #EarlyDetection

Lung adenocarcinomas with #mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors - Annals of Oncology annalsofoncology.org/article/S0923-…

We’re thrilled to announce the launch of Center for RAS Therapeutics to target the RAS oncogene in cancer. The first of its kind Center aims to advance new treatment approaches for patients with RAS mutant cancers. Learn more: bit.ly/3BobmtB

Hiring 🌟 Associate Director 🌟 @ DFCI Center for RAS Therapeutics/ Office of Strategic Partnerships Join a group of brilliant, internationally known investigators who inspire me daily & work @ the cutting edge of drug development careers.dana-farber.org/job/10912/asso… #lcsm #MedTwitter

New online! Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck nature.com/articles/s4157…

🔥 NatureRevClinOncol 🆙 ✅Hiding in plain sight: NUT carcinoma is an unrecognized subtype of squamous cell carcinoma of the lungs and head and neck 🎯A reclassification of NUT carcinoma as an SCC 👥Jia Luo, MD #LCSM OncoAlert nature.com/articles/s4157…

WHAT A WONDERFUL DISCUSSION! Discussing NUT Carcinoma and Mesothelioma with these amazing ladies Dr. Melina Marmarelis and Jia Luo, MD at #TTLC25 IASLC

DFCI Thoracic Oncology Team at #TTLC25! IASLC Julia Rotow MD Jacob sands Jia Luo, MD Narjust Florez, MD, FASCO David Barbie

🎙️ LIVE from #TTLC25! Narjust Florez, MD, FASCO Jia Luo, MD & Dr. Melina Marmarelis discuss two of the most challenging thoracic malignancies—NUT carcinoma & mesothelioma on #LungCancerConsidered. Learn about diagnosis, mutations & targeted therapy. 🎧 Listen now: bit.ly/TTLC24Live1

Dr. Jia Luo, MD reviews and emphasizes when to suspicious that your patient may have a #NUT carcinomas. We need to ensure that we are using RNA-based NGS testing and/or NUT IHC. #TTLC25 #lcam #lcsm IASLC

Featured today by MSK Library: Lung adenocarcinomas with mucinous histology: clinical, genomic, and immune microenvironment characterization and outcomes to immunotherapy-based treatments and KRASG12C inhibitors dx.doi.org/10.1016/j.anno… #LungCancer #Adenocarcinoma

✨EXCLUSIVE PREVIEW✨: Ahead of #AACR25, we asked leading oncologists which abstracts they’re looking forward to. James J. Harding, MD Jia Luo, MD Ravi Uppaluri, MDPhD Memorial Sloan Kettering Cancer Center Dana-Farber MD Anderson Cancer Center AACR #oncology Sign up to access the full preview here:🔗 onclive.com/view/oncology-…

KRAS research at #AACR25: Study of next-gen KRAS G12C inhibitor divarasib plus SHP2 inhibition showed activity in treatment of KRAS G12C-positive non-small cell lung cancer (#NSCLC). Patients mostly tolerated the treatment with some dose reductions.

At #AACR25, Jia Luo, MD, MD, Dana-Farber presents a late-breaking abstract on the clinical activity of daraxonrasib in KRAS mutant non-small cell lung cancer (#NSCLC), finding early clearance in circulating tumor DNA predicted partial response or stable disease.

Thank you to Jia Luo, MD of Dana-Farber for sharing updates at #AACR25 on early ctDNA reduction with daraxonrasib in RAS-mutant NSCLC and new findings from the divarasib + migoprotafib combo in KRAS G12C+ disease. Learn more at OncLive.com. AACR #lcsm #oncology